Amarin Again Dodges Securities Suit Over Vascepa Denial
A New Jersey federal judge on Tuesday again dismissed a securities class action against biopharmaceuticals maker Amarin claiming it failed to fully inform investors about its progress during a failed bid...To view the full article, register now.
Already a subscriber? Click here to view full article